Indo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Results View source PDF Explain this filing

INDOUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.4%Reaction day

₹150.00

prior close

₹151.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+4.5% vs market

Other Agricultural Products peers, median of 55sector-0.4%+4.8% vs sector

On the reaction day the stock moved 4.5 pts more than Nifty Microcap 250 and 4.8 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+1.1

15m

+0.2

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.4-0.1+4.5-0.4+4.8

Next day

+9.6+0.2+9.4+0.0+9.6

+14.7+0.6+14.1-0.7+15.4

+12.9+0.9+12.0-1.8+14.7

+8.6+1.0+7.6-1.9+10.6

+4.1+0.7+3.4-2.0+6.1

+6.3+1.8+4.6-1.3+7.7

15d

+0.7+1.7-1.0-1.7+2.4

+3.2+3.1+0.1-2.6+5.7

+7.6+1.7+5.9-5.5+13.1

+0.0-1.0+1.0-8.9+8.9

UpDownMarket · Nifty Microcap 250Sector · Other Agricultural Products peers, median of 55Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indo Us Biotech Limited has submitted its financial results for the period ending March 31, 2025 to the NSE. The filing relates to the company's fourth quarter and full-year results for FY25. No specific financial figures, growth rates, or auditor remarks were provided in this announcement notice itself. Investors would need to refer to the actual results document for detailed numbers and management commentary.

Likely market impact

This is a routine regulatory filing and does not by itself indicate any positive or negative development for shareholders. The actual financial performance and any notable items should be reviewed from the detailed results document.